Pfizer-Allergan collapse contributes to record period for cancelled M&A

William Turvill
Follow William
Pfizer In Merger Talks With Allergan PLC
Pfizer's $160bn merger with Allergan collapsed in April (Source: Getty)

The first half of 2016 was a record period for cancelled deals, new figures show.

The most high-profile withdrawal during the period was the $160bn (£124bn) Pfizer-Allergan merger, which was scuppered by US inversion rule changes.

Read more: The bitter pill of America's new tax law

Dealogic figures for the six-month period show that the number of cancelled deals was down nine per cent on the first half of 2015.

But the value of the transactions, which totalled $606.4bn, made it the highest first-half on record for withdrawn deals.

This was helped by the fact that 10 of the deals were valued at $10bn or more.

Read more: Brexit and Donald Trump expected to hit already falling M&A activity levels

The record period for withdrawn mergers and acquisitions (M&A) comes after a bumper 2015 in which more than $5 trillion worth of deals were announced.

The Pfizer-Allergan deal was one of the many deals announced in 2015, and represents the biggest withdrawn deal on record.

The next biggest deal collapse tracked by Dealogic was Honeywell’s $103bn pursuit of United Technologies. This deal fell apart in March.

Related articles